| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3291 | Mdmb-chminaca | Potent ligand of the central CB1 receptor |
|
| DCC3292 | Me1111 | Novel selective inhibitor of succinate dehydrogenase (complex II) of dermatophyte species |
|
| DCC3293 | me6tren Tetrahydrochloride | Potent and efficacious mobilizing agent of hematopoietic stem and progenitor cells (HSPCs), activating MMP-9 expression and disrupting the SDF-1α/CXCR4 axis, exhibiting more significant mobilizing effects than G-CSF or AMD3100 |
|
| DCC3294 | Mebeverine Hydrochloride Featured | Second generation papaverine analog, acting as an anticholinergic agent |
|
| DCC3295 | Mebhydrolin | Selective FXR antagonist, ameliorates glucose homeostasis in type 2 diabetic mice |
|
| DCC3296 | Medermycin | Polyketide antibiotic, acting as a AKT selective kinase inhibitor, alkylating a regulatory loop cysteine |
|
| DCC3297 | Medrogestone | Progestational hormone, for the treatment of menstrual irregularities, prostatic hypertrophy, and endometrial carcinoma |
|
| DCC3298 | Me-indoxam | Potent sPLA2 inhibitor, having no effect on arachidonic acid release and platelet activating factor synthesis |
|
| DCC3299 | mel_s3 | Inducer of Megakaryocyte Differentiation in Erythroleukemia Cells, Impairing Bcr-Abl Signaling Cascades |
|
| DCC3300 | Melafolone | Natural dual inhibitor of COX-2 and EGFR, improving program death 1 (PD-1) checkpoint blockade therapy through normalizing tumor vasculature and PD-L1 downregulation |
|
| DCC3301 | Melarsoprol | Prodrug of melarsen oxide (Mel Ox), irreversibly binding to vicinal sulfhydryl groups on pyruvate kinase, disrupting energy production in the parasite |
|
| DCC3302 | Melinamide | Inhibitor of cholesterol esterification |
|
| DCC3303 | Melk-in-c1 | Novel Multi-Kinase Inhibitor, Triggering Mitotic Catastrophe of Glioma Stem Cells Mainly through MELK Kinase Inhibition |
|
| DCC3304 | Melogliptin | Potent, selective and orally bioavailable inhibitor of dipeptidyl peptidase 4 (DPP-4) |
|
| DCC3305 | Melperone Hydrochloride | 5-HT2A/D2 receptor antagonist |
|
| DCC3306 | Men16132 | Novel potent and selective nonpeptide kinin B2 receptor antagonist |
|
| DCC3307 | meridianin A | Novel Cell Death-Inducing Kinase Inhibitor with Enhanced Selectivity for Cyclin-Dependent Kinases; Antimalarial |
|
| DCC3308 | Meriolin 3 | Potent cell-permeable, ATP site-targeting inhibitor of CDKs |
|
| DCC3309 | Meriolin 5 | Potent cell-permeable, ATP site-targeting inhibitor of CDKs |
|
| DCC3310 | Merodantoin | Apoptosis inducer, triggering ROS dependent autophagy-associated apoptosis in a variety of human cancer cell lines and against mutant KRAS expressing cancer cells involving AKT-dependent ROS production |
|
| DCC3311 | Meso-dihydroguaiaretic Acid | LXR-α antagonist, inhibiting hepatic lipid accumulation by activating AMP-activated protein kinase in human HepG2 cells |
|
| DCC3312 | Mesterolone | Anabolic and androgenic agent |
|
| DCC3313 | Mesyl Salvinorin B | Novel selective and potent full KOP receptor agonist with fewer side effects (e.g., sedation or anhedonia) than classic KOP receptor |
|
| DCC3314 | Metabolex-36 | Novel selective GPR120 agonist |
|
| DCC3315 | Metamizole | Cyclooxygenase 3 (COX3) inhibitor, acting as a potent inductor of cytochrome P450 isoenzymes CYP2B6 and CYP3A4 |
|
| DCC3316 | Methocinnamox | Potent, long-lasting, and selective antagonist of morphine-mediated antinociception |
|
| DCC3317 | Methoxybrassinin | Natural potent anti-proliferative agent, inducing apoptotic cell death |
|
| DCC3318 | Methoxyluteolin | Inhibitor of pro-inflammatory mediator release from mast cells |
|
| DCC3319 | Methyl 6-bromo-1h-indazole-4-carboxylate | Useful pharmaceutical building block |
|
| DCC3320 | Methyl Meso-(meta-pyridinium) Bodipy | Novel photosensitizer as a photodynamic antimicrobial agent against Staphylococcus aureus, Escherichia coli, Candida albicans, and Methicillin-resistant S. aureus (MRSA) |
|
